U.S. Federal Trade Commission: Complaint issued against Bristol-Myers Squibb
MLex Summary: The Federal Trade Commission issued a complaint against Bristol-Myers Squibb for paying generics to stay off the market for its brand name drug Plavix. ...To view the full article, register now.
Already a subscriber? Click here to view full article